Treatment of Parkinson's disease: disagreements

Comment

M Schulzer. Ann Neurol. 1997 Jun.

. 1997 Jun;41(6):833-4.

doi: 10.1002/ana.410410622.

No abstract available

Comment on

The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J. Olanow CW, et al. Ann Neurol. 1995 Nov;38(5):771-7. doi: 10.1002/ana.410380512. Ann Neurol. 1995. PMID: 7486869 Clinical Trial.
Deprenyl's neuroprotective action remains unresolved.
van Hilten JJ, Bloem BR, Klaassen AA. van Hilten JJ, et al. Ann Neurol. 1996 Aug;40(2):266-7. doi: 10.1002/ana.410400226. Ann Neurol. 1996. PMID: 8773615 No abstract available.
Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS, Fazzini E, Volkow ND. Fowler JS, et al. Ann Neurol. 1996 Aug;40(2):267-8. doi: 10.1002/ana.410400228. Ann Neurol. 1996. PMID: 8773616 No abstract available.
Deprenyl in Parkinson's disease.
Korczyn AD, Nisipeanu P. Korczyn AD, et al. Ann Neurol. 1996 Aug;40(2):268-9. doi: 10.1002/ana.410400229. Ann Neurol. 1996. PMID: 8773617 No abstract available.